Get the Stockscreener App
1.58
1.28%
0.02
Imunon Inc stock is traded at $1.58, with a volume of 34,009.
It is up +1.28% in the last 24 hours and down -5.39% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
See More
Previous Close:
$1.56
Open:
$1.56
24h Volume:
34,009
Relative Volume:
0.28
Market Cap:
$8.87M
Revenue:
$125.00K
Net Income/Loss:
$-14.64M
P/E Ratio:
-0.3058
EPS:
-5.1674
Net Cash Flow:
$-15.06M
1W Performance:
-1.25%
1M Performance:
-5.39%
6M Performance:
-54.34%
1Y Performance:
-72.38%
1-Day Range:
$1.54
$1.58
1-Week Range:
$1.5066
$1.64
52-Week Range:
$1.47
$6.025
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
1.58 | 8.87M | 125.00K | -14.64M | -15.06M | -5.1674 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Imunon Inc Stock (IMNN) Latest News
Imunon (IMNN) Q2 2026 Filing Snapshot: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Stock Move: Shares Move 1.25% Lower on the DayEarnings Revision Upgrade - vinanet.vn
Imunon (IMNN) General Counsel and Corp Sec Susan Eylward Sells 2,449 Shares - GuruFocus
Imunon (IMNN) pays executive chair with 7,147 shares - Stock Titan
Imunon (IMNN) CEO takes 6,615 shares instead of cash pay - Stock Titan
Imunon (IMNN) pays CMO with 3,516-share stock grant - Stock Titan
Imunon (IMNN) counsel gets stock in lieu of pay, then sells 2,449 shares - Stock Titan
Imunon General Counsel Susan Eylward disposes of 2,449 common shares worth $3,992.54 - Bitget
Imunon (IMNN) Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 4.43% BounceProduct Revenue Analysis - vinanet.vn
Imunon Inc. (IMNN) Advances 4.43% as Biotech Stock Tests Key Resistance at $1.73Fair Value Gap - dars.gov.et
Imunon Inc (NASDAQ: IMNN) Share Price, IMNN Stock News, IMNN Share Price & Updates - Kalkine
Armistice Capital (IMNN) discloses 9.99% Imunon stake via Master Fund - Stock Titan
IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025 - kalkine.ca
Earnings call transcript: Imunon beats Q2 2026 EPS forecast as shares stay weak - Investing.com UK
Imunon (IMNN) Q2 2026 Earnings Call Transcript - The Globe and Mail
Imunon Q2 2026 Loss Shrinks 42.6%: -$0.54/Share vs -$0.94 Expected - AlphaStreet
Imunon Q2 2026 Earnings Call Transcript - MarketBeat
Imunon Adopts New Equity-Based Executive Compensation Program - TipRanks
Imunon, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form 8K Imunon Inc For: 11 August By Investing.com - Investing.com Australia
Q2 2026 Imunon Inc Earnings Call Transcript - GuruFocus
Imunon Inc (IMNN) Advances Phase 3 Trial Amidst Challenging Valu - GuruFocus
Imunon, Inc. 2Q 2026: Net loss $(2.83M), EPS $(0.54) — 10-Q Summary - TradingView
IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Imunon Q2 net loss widens slightly as R&D costs rise - tradingview.com
IMUNON reports $2.8 million Q2 loss as OVATION 3 enrollment advances - Quiver Quantitative
Imunon reports Q2 2026 net loss $2.8M; cash $6.9M, advances Phase 3 OVATION 3 - TradingView
BRIEF-Imunon Q2 EPS USD -0.54 - TradingView
IMNN Q2 2026 Earnings: EPS Loss of $0.54 Beats Estimates by 42.83%; Stock Rises 0.61Quarterly Earnings Report - vinanet.vn
IMNN Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesEarnings Cycle Outlook - vinanet.vn
Imunon Inc expected to post a loss of 93 cents a shareEarnings Preview - TradingView
Imunon Inc. (CBO0.SG) cash flow - Yahoo Finance UK
Imunon (IMNN.US) will release its earnings report on August 11. - Moomoo
Imunon (IMNN) General Counsel Susan Eylward Sells 2,541 Shares - GuruFocus
Imunon, Inc. (IMNN) director granted 6,934 shares in lieu of fees - stocktitan.net
Imunon (IMNN) director granted 6,934 shares of stock for board fees - Stock Titan
Imunon (IMNN) grants director 6,934 shares instead of cash board fees - Stock Titan
Imunon (NASDAQ: IMNN) awards director 6,180 shares for board fees - Stock Titan
Imunon, Inc. (IMNN) general counsel grants and sells 2,541 shares - stocktitan.net
Imunon, Inc. (IMNN) grants chair 6,358 shares instead of cash salary - Stock Titan
Imunon, Inc. (IMNN) CMO granted stock in lieu of cash pay - Stock Titan
Imunon, Inc. (IMNN) CEO awarded 5,010-share stock grant as compensation - Stock Titan
IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026 - The Manila Times
Imunon Inc. (IMNN) Q1 2026 Earnings: Narrower Net Loss Beats Expectations, Shares Edge HigherEarnings Deceleration Risk - vinanet.vn
Imunon (IMNN.US) will release its earnings report on August 4. - Moomoo
IMUNON reports faster-than-expected enrollment in ovarian cancer trial By Investing.com - Investing.com Nigeria
IMUNON Reports Faster-Than-Expected Enrollment in Phase 3 OVATION 3 Trial of IMNN-001 for Advanced Ovarian Cancer - Quiver Quantitative
IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer - GlobeNewswire
Imunon Q1 2026 Earnings: EPS Surprises to the Upside as Narrower Loss Beats EstimatesEarnings Per Share - vinanet.vn
IMNN|Imunon Inc|Price:1.514|Chg%:+0.004 - TradingKey
Imunon Inc (IMNN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Imunon Inc Stock (IMNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Eylward Susan | General Counsel and Corp Sec |
Aug 17 '26 |
Sale |
1.63 |
2,449 |
3,993 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Aug 03 '26 |
Sale |
1.57 |
2,541 |
3,977 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Jul 20 '26 |
Sale |
1.78 |
2,150 |
3,830 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Jul 06 '26 |
Sale |
1.88 |
920 |
1,730 |
2,896 |
| Eylward Susan | General Counsel and Corp Sec |
Jun 29 '26 |
Sale |
1.75 |
11,800 |
20,674 |
2,896 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):